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Abstract The lower sensitivity of the inflamed nasalmucosa to glucocorticoids might be related to an increased ex-
pression ofthe glucocorticoidreceptor (GR) beta isoform.Weinvestigated GRa and GRbmRNAexpression in epithelial
cells fromnasalmucosa andnasalpolyps.GRamRNAwas at least1000 timesmore expressed than GRbmRNAinboth
tissues.GRb expression (mean7SEM of 103 cDNA copies/mg of total RNA) was higher in nasal polyps (1.1570.19; n=27;
Po0.01) than in nasal mucosa (0.6270.10; n=32).Nasal polyps with43% of inflammatory cells had higher GRb levels
(1.4070.29; n=16) than both nasal mucosa (Po0.01) and polyps with r3% of inflammatory cells (0.8070.18; n=11;
Po0.05).No differenceinGRbexpressionwas foundbetweennasalmucosa andpolypswithr 3% of inflammatorycells.
GRb expression correlated with the inflammatory cell number, especially with mast cells (r=0.50, Po0.0001). There
was no difference in GRamRNA expression between nasalmucosa and nasal polyps. In summary,GRa is far more ex-
pressedthanGRb inbothtissues.Theincreasedexpressionof GRbmayberelatedtothepresence of inflammatorycells.
r 2002 Elsevier Science Ltd.Allrights reserved.
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Nasal polyps are evaginations from the sinusmucosa and
the middle turbinate that are in¢ltrated with in£amma-
tory cells, mainly eosinophils and mast cells (1,2). Gluco-
corticoids are the most frequently administered drugs
with a proven e¡ect on reducing polyp size and in£am-
mation. However, not all patients with nasal polyposis
respond to corticosteroid treatment, some of them re-
quire surgery despite glucocorticoid maintenance ther-
apy (1). These observations suggest that nasal polyps
consist of a tissue relatively resistant to glucocorticoids,
but the underlying mechanisms leading to this poor re-
sponse are as yet unclear.
Wepreviouslyreported that some cytokines secreted
by nasal mucosa and nasal polyp epithelial cells enhanceReceived 2 April 2002, accepted in revised form12 June 2002
Correspondence should be addressed to:Dr CeŁ sar Picado,MD, Servei
de Pneumologia,Hospital Cl|¤nic,C/ Villarroel170, 08036 Barcelona,
Catalonia, Spain.Fax: +34 93 4515272; E-mail: cpicado@medicina.ub.eseosinophil survival (2). We also found that glucocorti-
coids inhibit the survival-promoting e¡ect of the epithe-
lial cell secretions, but this e¡ect was less potent in
epithelial secretions fromnasalpolyps than in those from
healthy nasalmucosa (2).This ¢nding suggested a relative
resistance of nasal polyp epithelial cells to the e¡ect of
glucocorticoids.
Suboptimal response to glucocorticoids has been
described in a number of diseases but it has been mainly
investigated in bronchial asthma.The asthmatic patients
who are at the lower end of the glucocorticoid response
range are considered to be glucocorticoid resistant (3).
The rationale of our study is based on the fact that nasal
and bronchial diseases should be part of the same
pathogenic process and that the mechanisms involving
glucocorticoid dependence/resistance in asthma may
also account for nasal polyposis.
The biological action of glucocorticoids is mediated
through activation of intracellular glucocorticoid
receptors (GRs) (4). Two human isoforms of GR have
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same gene by alternative splicing of the GR primary
transcript (5).Uponhormonebinding,GRa is phosphory-
lated, dissociated from heat shock proteins and
translocated to the cell nucleus. As a homodimer, GRa
binds to speci¢c sequences within the promoter region
of target genes, leading to an enhancement or a
repression of their transcription. However, most of the
antiin£ammatorye¡ects of glucocorticoids aremediated
through protein^protein interactions between GR
and transcription factors, such as AP-1 and NF-kB (6).
The GRb isoform di¡ers from GRa in its carboxy
terminus, where the last 50 amino acids of GRa are
replaced by a non-homologous 15 amino acid sequence.
GRb neither binds glucocorticoids nor trans-activates
target genes (5,7). Transfection studies have revealed
the ability of GRb to act as a dominant negative inhibitor
of GRa activity (5,8) through a mechanism that involves
the formation of transcriptionally impaired GRa-GRb
heterodimers (8). However, other studies have chal-
lenged this concept (7,9,10).
There may be several mechanisms accounting for
the resistance to the antiin£ammatory e¡ects of gluco-
corticoids. Certain proin£ammatory cytokines may
induce activation of the transcription factor AP-1,
which would block the activated GRa, thereby leading
to an impaired suppression of the in£ammatoryresponse
(11). Another suggested mechanism is the cytokine-
driven reduction of the GRa binding a⁄nity for gluco-
corticoids (12). An overexpression ofGRbmay also be in-
volved in glucocorticoid-resistant diseases. Thus,
increased expression of GRb has been reported in pa-
tients with glucocorticoid-insensitive asthma (13^15), ul-
cerative colitis (16), nasal polyps (17) and in one patient
with systemic glucocorticoid resistance and chronic lym-
phocytic leukemia (18). Downregulation of GRa levels
after treatment with glucocorticoids (19^21) has also
been postulated to be one of the possible explanations
for the secondary glucocorticoid resistance phenomen-
on (6).
We hypothesized that the lower sensitivity of the na-
sal polyp epithelia to glucocorticoids might be due, at
least in part, to an increased expression of GRb in
epithelial cells. This study was designed to test this hy-
pothesis.
SUBJECTSANDMETHODS
Subjects
Human nasalmucosa was obtained from 32 healthy sub-
jects (20 males) aged 30.372.4 years, undergoing nasal
corrective surgery for turbinate hypertrophy or septal
dismorphy.None of the subjects were treated with cor-
ticosteroids. The skin-prick test for common allergenswas positive in ¢ve subjects (16%) and negative in 27
(84%).
Nasal polyps were obtained from 27 patients (19
males) aged 4772.6 years, undergoing nasal polypect-
omy. At the time when polypectomy was carried out,
eight patients (30%) were receiving intranasal corticos-
teroids (£uticasone or budesonide, 200^400mg/day),
one (4%) was receiving oral prednisone (40mg/day), and
six (22%) were receiving both intranasal (budesonide or
£uticasone,400mg/day) andoral corticosteroids (predni-
sone or de£azacort, 20^40mg/day). The remaining 12
patients (44%) had not received steroid treatment for at
least1month prior to surgery.Twelve subjects (44%) had
asthma, half of these were aspirin-intolerant. The skin-
prick test was positive in ¢ve patients (18%), negative in
16 (59%), and it couldnotbe determined in the remaining
six patients (22%).The study was approvedby the Ethics
Committee of our Institution.
Preparation of epithelial cell extracts
Freshlyobtainednasalmucosa andnasalpolyp specimens
were digested with protease and nasal epithelial cell ex-
tracts were isolated as previously reported (2).Cell via-
bility was assessed by trypan blue dye exclusion in a
haemocytometer. Cell population was histologically
characterized using smears obtained by cytocentrifuga-
tion (500 rpm,10min) and stainedwithMay^Grˇnwald^
Giemsa (MGG). After tissue protease digestion, cell via-
bility was 9470.8% for nasal mucosa and 9570.9% for
nasal polyps. Compared with healthy mucosa, nasal
polyps provided a signi¢cantly larger percentage of eosi-
nophils, neutrophils and metachromatic cells (Table 1).
Previous studies have shown thatmost of themetachro-
matic cells identi¢ed in nasal polyps through histochem-
ical staining methods correspond to mast cells, as
identi¢ed using immunohistochemical staining protocols
(22).The percentage of each in£ammatory cell type was
not signi¢cantly di¡erent in asthmatics with respect to
non-asthmatics. However, there was a tendency for a
higher number of eosinophils in patients with aspirin-in-
tolerant asthma (12.372.5%; n=6) compared to aspirin-
tolerant asthmatics (6.471.6%; n=21; P=0.087). There
was no di¡erence in the individual in£ammatory cell
count between the glucocorticoid-treated polyps and
the non-treated ones. Nasal polyps with a positive skin-
prick test provided a higher number of neutrophils
(471%; n=5) than those with a negative skin-prick test
(1.870.3%; n=16; Po0.05). There was no di¡erence be-
tween these two groups of patients with respect to the
cell counts of all other in£ammatory cell types.
Nasal polyp cell extracts, which had a higher percen-
tage of in£ammatory cells than those of nasal
mucosa, were processed for panning with an ICAM-3
antibody that e⁄ciently recognizes the ICAM-3 antigen
TABLE 1. Cellpopulations obtained after protease digestion and cellpanning of nasalmucosa andnasalpolyps
After protease digestion After panning
NM NP All NP NP (r3% IC) NP (43% IC)
n 32 27 27 11 16
Total in£amm. cells (%) 2.570.3 13.571.6a 6.071.1a 1.770.3 9.071.4a,b
Eosinophils (%) 0.070.0 7.771.4a 2.670.9a 0.370.1 4.271.3a,b
Lymphocytes (%) 0.670.2 0.970.2 0.570.2 0.270.1 0.770.3
Metachromatic cells (%) 0.370.1 2.470.3a 1.470.2a 0.970.2a 1.770.3a,b
Neutrophils (%) 1.670.2 2.570.4a 1.570.3 0.470.1a 2.370.41a,b
NM,NPand ICdenote nasalmucosa, nasalpolyp and in£ammatorycells, respectively.
aPo0.05, comparedwith NM.
bPo0.05, comparedwith NP withr3% IC.
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bated for 1h at 41C on a Petri dish preabsorbed with
the ICAM-3 antibody and were subsequently washed,
centrifuged and characterized by MGG staining. After
cell panning thepercentage of in£ammatorycellswas re-
duced to 6.071.1%, but it was still signi¢cantly higher
than in nasal mucosa (2.570.3%) (Table 1).To normalize
the in£ammatory cell content of polyps to that of nasal
mucosa, polyps were classi¢ed into two groups: those
which had a percentage of in£ammatory cells similar to
that of nasalmucosa, i.e.r3%, and thosewith an in£am-
matory cell content43% (Table 1). Finally, 3^10106 of
total cells from either nasal mucosa or nasal polyp
epithelial cell extracts were pelleted and frozen at
801Cuntil RNA analysis.
Reverse transcriptionFcompetitive PCR
Total RNA from nasal mucosa and nasal polyp epithelial
cells was isolated using a rapid extraction method (TRI-
Reagent) and reverse transcribed to complementary
DNA (cDNA), as previously described (20). GRa and
GRb cDNAs were analyzed by competitive PCR, which
is an accurate and sensitive method to quantify gene ex-
pression (24,25).This technique is based on the coampli-
¢cation of the target cDNA and known amounts of an
exogenousDNA, calledcompetitor or internal standard,
in the same test tube (20). Since the initial amount of in-
ternal standard was known, the initial amount of target
cDNAwas determined.
GRa and GRb PCR reactions were performed before
reaching the plateau phase. Primers were designed to
span introns, so that any genomic DNA product
would be distinguished from the target cDNA by size
di¡erence. GRa and GRb cDNAs were ampli¢ed using
speci¢c antisense primers that shared the same sense
primer, whose sequences were as follows: 50 -
GGCAATACCAGGTTTCAGGAACTTACA-30 (GRa/b
sense), 50 -ATTTCACCATCTACTCTCCCATCACTG-30(GRa antisense), and 50 -ATTATCCAGCACTTCATAGA-
CACAAAT-30 (GRb antisense), corresponding to nu-
cleotide start positions 1869, 2692, and 2870,
respectively. The PCR reaction and cycling conditions
have been extensively described elsewhere (20). Both,
GRa- and GRb-speci¢c primers ampli¢ed their respec-
tive target cDNA and competitor with the same e⁄-
ciency. In addition, this competitive PCR assay was
sensitive enough to detect two-fold di¡erences inGR ex-
pression.
To ensure that the RNAwas e¡ectively reverse tran-
scribed to cDNA, the PCR for the housekeeping gene
glyceraldehyde-3-phosphate dehydrogenase was routi-
nely performed for each sample.
Statistical data analysis
The expression of GRa or GRb mRNA is expressed as
the arithmetic mean7standard error of the mean (SEM)
of103 copies of GRa or GRb cDNAper mg of total RNA.
Statistical comparisons were performedusing analysis of
variance (ANOVA) with the Dunnett t-test. Po0.05 was
regarded as statistically signi¢cant.
RESULTS
The expression of GRa mRNA was much higher than
GRbmRNA expression in all specimens.Thus, the GRa/
GRb ratio was 32247402 for nasal mucosa (n=32) and
17227289 for the nasal polyp epithelial cell extracts
(n=27;Po0.01).
However, there was a higher expression of GRb
mRNA (103 cDNA copies/mg of total RNA) in the
epithelial cell extracts from nasal polyps (1.1570.19;
Po0.01) than in those from nasal mucosa (0.6270.10).
After classifying the nasal polyps into two groups, ac-
cording to their in£ammatory cell content, we found an
evenmore increased expression of GRbmRNA in those
polyps that had more than 3% of in£ammatory cells
FIG. 1. Expression of GRa and GRbmRNA in nasal mucosa and nasal polyp epithelial cell extracts with either r3% or43% of
in£ammatory cells.Total cellular RNA fromnasalmucosa and nasal polyp epithelial cell extractswas isolated and reverse transcribed
to cDNA.GRa andGRb cDNAswere ampli¢edbycompetitive PCRusing GRa- andGRb-speci¢c primers.Four serial dilutions ofthe
competitors (internal standard,GRa-S or GRb-S) were added to a constant amount of target cDNA. After ampli¢cation, the PCR
productswere resolved by agarose gel electrophoresis and ethidumbromide staining.The relative amounts of target and GR-S pro-
ducts,whichdi¡eredinsize,were analyzedandcomparedineachsamplebydensitometric analysis.Becausethe amountofGR-Sadded
to each PCR reactionwasknown, the absoluteinitial amountoftargetcouldbedetermined.Insets showrepresentativegelsoftheGRa
and GRbPCRproducts, with four increasingdilutions of GRa-S (1091bp) or GRb-S (1118 bp), which competewith a constant amountof
the targetcDNA (GRa, 824 bp;GRb,1002 bp).
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compared to both nasal mucosa (Po0.01) and polyps
with r3% of in£ammatory cells (0.8070.18; GRa/GRb
ratio=22307395; n=11; Po0.05) (Fig. 1). However, no
statistical di¡erence in GRb mRNA expression was
found between nasal mucosa and nasal polyps with
r3% of in£ammatory cells. In addition, a linear correla-
tionwas foundbetween GRbmRNA expression and the
percentage of in£ammatory cells in all studied specimens
(r=0.38; n=59; Po0.01) (Fig. 2). More speci¢cally, there
was strong correlation between GRb expression and
the number of metachromatic cells in all specimens
(r=0.50; n=59; Po0.0001) (Fig. 2), as well as in all nasal
polyps (r=0.49; n=27;Po0.01) andnasalpolypswithmore
than 3% of in£ammatory cells (r=0.60; n=16;Po0.05).No
correlation was found between GRbmRNA expression
and other in£ammatory cells (neutrophils, eosinophils
and lymphocytes) (Fig. 2).
In contrast, no di¡erences in GRa mRNA expression
were found between nasal mucosa (16907240; n=32)
and all nasal polyps (13707190; n=27; NS), nor between
nasal mucosa and polyps with either less (16707410;
n=11; NS) or more (11707160; n=16; NS) than 3% of in-
£ammatory cells (Fig. 1). There was no correlation be-
tween GRa mRNA expression and the in£ammatory
cell count.No di¡erences in the expression of GRa or GRb
mRNA were found between asthmatics (GRa=
15607310; GRb=1.2970.26; n=12) and non-asthmatic
subjects (GRa=12307250; GRb=1.0370.28; n=15), nor
between aspirin-tolerant (GRa=14707240; GRb=
1.1370.23; n=21) and aspirin-intolerant asthmatics
(GRa=10507200; GRb=1.2070.35; n=6).No signi¢cant
di¡erences in either GRa or GRb mRNA expression
were found between glucocorticoid-treated polyps
(GRa=11907160; GRb=1.2470.28; n=15) and non-trea-
ted polyps (GRa=16007390; GRb=1.0370.26; n=12). In
nasalmucosa specimens, no di¡erences in the expression
of GRa or GRb were found between atopic (GRa=
18007730; GRb=0.6370.18; n=5) and non-atopic sub-
jects (GRa=16607260; GRb=0.6270.12; n=27). Simi-
larly, the expression of both GR isoforms in nasal polyps
was similar between atopic (GRa=12107540; GRb=
0.8570.40; n=5) and non-atopic patients (GRa=15307
270; GRb=1.3570.25; n=16).
DISCUSSION
It iswell established that somepatientswith nasal polyps
fail to respond to glucocorticoid therapy (1).On the basis
of our previous studies suggesting a relative resistance of
FIG. 2. Correlation between GRb expression and the percentage of in£ammatory cells in nasalmucosa and nasal polyps.Total cel-
lular RNAfromnasalmucosa andnasalpolyp epithelialcellextractswasisolatedandanalyzedby RT-competitve PCR.GRbexpression
levelswere correlated (r) withthe in£ammatorycells present in the nasal epithelial cell extracts.
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of glucocorticoids (2), we hypothesized that nasal polyp
epithelial cells might mediate part of this resistance
through overexpression of the GRb isoform.The aim of
this study was to evaluate the expression of GRa and
GRb isoforms in epithelial cell extracts fromnasalmuco-
sa and nasal polyps.Themain ¢ndings of our study were:
(1) GRa mRNA expression was more than 1000 times
higher than thatofGRb inboth nasalmucosa andpolyps,
(2) GRb expressionwas higher in nasal polyps than in na-
sal mucosa, (3) the increased expression of GRb in nasal
polyps correlatedwith the in£ammatory cell number.
The expression of GRbmRNAwas found to be much
less abundant than that of GRa in both nasal mucosa
(GRa/GRb ratio=32247402) and nasal polyps (GRa/
GRb ratio=17227289). These ¢ndings are in line with
RT-PCR andNorthernblot analysis performedonwhole
human tissues and cell lines (5,16,20,26^28). Oakley andcoworkers (5), using external standards to quantify the
GR transcripts, reported about 200^500 times more
GRa mRNA than GRb mRNA in two adult tissues and
two human cell lines. Using a semi-quantitative RT-PCR
approach, Honda and coworkers (16) detected GRb
mRNA in only10% of the PBMCs from healthy subjects.
The authors detected GRbmRNA in 83% of the PBMCs
from patients with glucocorticoid-resistant ulcerative
colitis, but its concentration was still 605 times lower
than the GRa message. Cell-type-speci¢c di¡erences or
di¡erences in the RT-PCR technique used may account
for the variability in theGRa/GRb ratio reported among
di¡erent investigators.Other researchers have even re-
quired the use of nested PCR to detect the GRb tran-
script (27).
At the protein level, Western blotting studies have
revealed little (7,16,29) or any GRb (20,27) in a variety
of cells and tissues. Immunohistochemical studies have
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cells (13^15,17,30^32).Thus,GRb has been detected in hu-
man neutrophils from healthy subjects (31), in airwayT-
cells (14,15) andmacrophages (15) from glucocorticoid-in-
sensitive asthmatics, and in in£ammatory cells from pa-
tients with nasal polyposis (17). The expression of GRb
in cell types of non-in£ammatory origin has been hardly
investigated. Oakley and coworkers (29) detected GRb
only in a few cell types within the whole tissue, namely,
the epithelial cells lining the terminal bronchiole of the
lung, forming the outer layer of Hassall’s corpuscle in
the thymus, and lining the bile duct in the liver.
An increased expression of GRbmRNAwas found in
epithelial cell extracts fromnasal polyps compared to na-
salmucosa, whichwasmore evident in those polyp sam-
ples containingmore than 3% of in£ammatory cells.The
higher expression of GRb in nasal polyps apparently ac-
counts for the in£ammatory cells that remained after
panning, for a correlation was found between GRb ex-
pression and the number of in£ammatory cells, espe-
cially mast cells, present in the epithelial cell extracts.
We are tempted to speculate that if we hadnot removed
the in£ammatory cell content from nasal polyps, we
would probably have found a more marked di¡erence in
the expression of GRb mRNA in nasal polyps with re-
spect to nasal mucosa. Indeed, Hamilos and coworkers
(17) have recently reported that GRb expression in nasal
polyps is con¢ned to in£ammatory cells, particularly T
lymphocytes, eosinophils, andmacrophages.The authors
also reported increased number of GRb-positive in£am-
matory cells in nasal polyps compared to control middle
turbinates. Our results showing increased GRb expres-
sion in epithelial cell extracts from nasal polyps are not
in contradictionwith those of Hamilos (17).Our ¢ndings
reveal that epithelial cells, as opposed to in£ammatory
cells, from either nasal mucosa or polyps do not signi¢-
cantly express GRb, and further reinforce the concept
that the expression ofGRb ismainlyrestricted to in£am-
matory cells. Contradicting our hypothesis, the relative
resistance of nasal polyp epithelial cells to the antiin£am-
matory e¡ect of glucocorticoids (2) does not account for
an overexpression of GRb in these cells.
The relationship between insensitivity to glucocorti-
coid treatment and increased expression of GRb has also
been reported in asthma (13^15,30), ulcerative colitis
(16), as well as in chronic lymphocytic leukemia asso-
ciated with systemic glucocorticoid resistance (18). In-
creased GRb has also been found in animal models of
systemic glucocorticoid resistance (33). However, other
investigatorshavenotobserved anycorrelationbetween
GRb expression and glucocorticoid insensitivity. For in-
stance,Gagliardo andcoworkers (27)wereunable to ¢nd
increased GRb expression in PBMCs from patients with
glucocorticoid-dependent asthma. Similarly, no signi¢-
cant di¡erences in GRb expression were observed in
both pituitary and ectopic ACTH-secreting tumors(26). In addition, the possible physiological role of GRb is
still a matter of debate (33,34). Cotransfection studies
have shown that when GRb is more abundant than
GRa, GRb acts as a dominant negative inhibitor of GRa
activity (5) through a mechanism which mostly involves
the formation of transcriptionally impaired GRa^GRb
heterodimers (8). However, other researches found no
evidence of a speci¢c dominant negative e¡ect of GRb
on GRa activity (7,9,10). Although certain cell types are
known to contain GRb, further studies analyzing the
GRa/GRb ratio are needed. In addition, the possible con-
tribution of a few cells overexpressing GRb to the dis-
ease condition is as yet unknown.
In summary, we report that GRamRNA expression is
far more abundant than the expression of GRb in both
nasal mucosa and nasal polyp epithelial cells. The in-
creased expression of GRbmRNA in nasal polyps corre-
lates with the number of in£ammatory cells present in
thenasalpolyp extracts.Our results suggest that epithe-
lial cells from either nasalmucosa or nasal polyps are not
a primary target for GRb expression.
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